Clinical Evaluation of Adriamycin, a New Antitumour AntibioticBr Med J 1969; 3 doi: https://doi.org/10.1136/bmj.3.5669.503 (Published 30 August 1969) Cite this as: Br Med J 1969;3:503
- Gianni Bonadonna,
- Silvio Monfardini,
- Mario de Lena,
- Franca Fossati-Bellani
Adriamycin, a new antitumour antibiotic of the anthracycline group with a structural formula very similar to daunorubicin, has proved to have potent tumour-growth-inhibiting properties, and to be particularly effective in childhood malignancies. Though adriamycin produces a higher percentage of side-effects than daunorubicin—namely, stomatitis and alopecia—a lower dosage may be used for therapy.